Ana Alarcão

Ana Alarcão

Auto-generated profile, based on publicly available information

Ana Alarcão

Instituto de Anatomia Patológica e Patologia Molecular, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2023 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
JSJoana Espírito Santo
Joana Espírito Santo
ALAna Ladeirinha
Ana Ladeirinha
AAAna Alarcão
Ana Alarcão
ESEugeniu Strelet
Eugeniu Strelet
Marco ReisMarco Reis
Marco Reis
LCLina Carvalho
Lina Carvalho

27 June 2025 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
LRLuís Vaz Rodrigues
Luís Vaz Rodrigues
MVMarta Viegas
Marta Viegas
ALAna Filipa Ladeirinha
Ana Filipa Ladeirinha
AAAna Alarcão
Ana Alarcão
LTLuis Taborda-Barata
Luis Taborda-Barata
VSVitor Sousa
Vitor Sousa
Objectives: The advent of massively parallel next-generation sequencing (MP-NGS) offers potential advantages over sequential molecular profiling (SMP) in the management of non-small cell lung cancer (NSCLC). This study compares the two methodologies using samples obtained through endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), focusing on actionable mutation detection, turnaround time (TAT), and clinical outcomes. Methods: A retrospective analysis was conducted on NSCLC patients who underwent EBUS-TBNA and molecular characterization between January 2020 and December 2023. SMP and MP-NGS were compared in terms of actionable mutation detection rates, TAT, and impact on overall survival (OS). Results: Among 106 patients, MP-NGS demonstrated a significantly higher detection rate of actionable mutations compared to SMP (40.9% vs. 22.2%, p=0.042). The median TAT was slightly shorter with SMP than with externally outsourced MP-NGS (17 days vs. 23 days, p=0.076). Patients diagnosed via MP-NGS were more frequently allocated to targeted therapies (44.26% vs. 22.2%, p=0.038), which may have positively influenced overall survival (672 days vs. 138 days, p=0.053). Conclusion: MP-NGS provided superior diagnostic and clinical advantages over SMP in NSCLC, supporting its adoption as a standard diagnostic approach to enhance personalized therapy and improve patient outcomes.